The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health told Reuters.
CVS is one of the largest U.S. pharmacy benefit managers and, along with rival Express Scripts, has put unprecedented pressure on global pharmaceutical makers to lower prices for its clients.
Iran’s foreign minister and chief negotiator in nuclear talks with the West declared victory for his country, stating that no matter how the negotiations end, Tehran has come out “the winner,” according to remarks made on Tuesday and presented in the country’s state-run press.
Javad Zarif, the Islamic Republic’s foreign minister, stated in remarks before the country’s powerful Assembly of Experts, which recently installed a hardline new cleric as its leader, that the nuclear negotiations have established Tehran as a global power broker.
“We are the winner whether the [nuclear] negotiations yield results or not,” Zarif was quoted as saying before the assembly by the Tasnim News Agency. “The capital we have obtained over the years is dignity and self-esteem, a capital that could not be retaken.”
Zarif’s comments were accompanied by a host of bold military displays by Tehran in recent weeks, including the announcement of one new weapon that Iranian military leaders have described as a “very special” missile.
As the United States and Iran rush to hash out a final nuclear agreement ahead of a self-imposed July deadline, Zarif also lashed out at congressional Republicans who have expressed skepticism over the Obama administration’s diplomacy and have fought to exert control over the implementation of any deal.
Zarif dismissed as a “propaganda ploy” a recent letter signed by 47 Senate Republicans that warned Tehran against placing too much stock in a weak deal agreed to by the Obama administration.
President Obama put several red lines for the Islamic Republic, but the ruling mullah breached the lines with no reaction from the White House. To save face, President Obama began making concessions and an unprecedented level of compromises.
At the first stage, President Obama and Secretary of State John Kerry allowed Iran to maintain the right to enrich uranium. Later, President Obama gave Iran the right to keep several hundred of its advanced centrifuges. The number later increased to a couple thousand, four thousand, and currently it is up to 6000.
In addition, President Obama made a concession to permit the Islamic Republic to maintain its heavy water plutonium reactor in Arak and continue constructing it soon.
Moreover, Obama and Kerry continued to make inaccurate statements to the public that Iran is “living up” to the requirements of the interim deal. According to the last week report from the IAEA, Iran still denies providing full access to information and its nuclear sites. Last week, the IAEA reported its concern, stating that the agency “remains concerned about the possible existence in Iran of undisclosed nuclear related activities involving military-related organizations, including activities related to the development of a nuclear payload for a missile.” The IAEA added that it cannot conclude that Iran’s nuclear activities are peaceful and that there are no “undeclared nuclear material and activities in Iran.”
There are other enrichment facilities. Check out Urenco and Louisiana Energy Services LES..
LEU has the best technology since GE cancelled he Silex plant.
In a recent report, analysts at JMP Securities expressed their bullish outlook for three stocks following meetings with company executives at the JMP Securities Technology Conference this week.
Here is a summary of what analysts had to say about the three names.
TubeMogul Inc (NASDAQ: TUBE)
Analysts have several major takeaways from their fireside chat with CFO Paul Joachim. According to Joachim, the company's future margin expansion will likely be driven by its transformation to Platform Direct, and investors can expect the company's investments in Programmatic TV and Display to rise in 2015.
Analysts believe that the recent 31 percent sell-off in TubeMogul shares is overdone.
"We continue to believe that TubeMogul is well-positioned to grow its share of the $70B+ domestic TV advertising market as advertisers increasingly follow audiences online, creating a positive risk/reward in the shares," they explain in the report.
JMP Securities has an Outperform rating on TubeMogul and a $21 target for the stock.
Shorting the stock into earnings was a great move, but now all the bad news is factored in and all the potential sellers have already sold.
The last short to cover may be doing so above $23 a share and given the current short percent of float, TUBE may see a short squeeze if they announce a big new contract.
Imagine if they get a buyout offer...
Columnist Dennis Prager: "Appeasers hate those who confront evil. Given that this president is the least likely of any president in American history to confront evil – or even identify it – while Benjamin Netanyahu is particularly vocal and eloquent about both identifying and confronting evil, it is inevitable that the former will resent the latter. ... [T]hose who refused to characterize the Soviet Union as evil loathed Ronald Reagan and other anti-communists for doing so; and those who objected to the 'Axis of Evil' label placed on North Korea, Iran, and Iraq loathed George W. Bush and his supporters. The loathing of Benjamin Netanyahu is simply the latest example of the rule that those who will not confront evil will instead confront those who do. (It’s much safer, after all.) "
Susan Rice told AIPAC It was ‘neither realistic nor achievable’ to expect Iran to stop enriching uranium:
‘We cannot let a totally unachievable ideal stand in the way of a good deal. I know that some of you will be urging Congress to insist that Iran forgo its domestic enrichment capacity entirely,’ Rice told AIPAC, as the crowd broke in to cheer.
‘But, but, but as desirable as that would be, it is neither realistic nor achievable.’
Didn't Obama list that as his number one foreign policy goal?
Late last week, Gilead Sciences, Inc. GILD announced detailed 48-week results from two phase III studies − Studies 104 and 111 − on an investigational once-daily single-tablet regimen containing tenofovir alafenamide (TAF). Both studies evaluated the TAF-containing tablets for the treatment of HIV-1 infection in treatment-naïve patients.
Based on these results, Gilead stated that its tenofovir alafenamide-containing investigational therapy was the first TAF-based regimen that was found to be non-inferior to Stribild and also enhanced in terms of renal and bone parameters. The company added that a TAF-based single-tablet regimen has the potential to address the needs of HIV patients undergoing life-long antiretroviral therapy.
Meanwhile, Gilead filed a new drug application for the E/C/F/TAF combination with the FDA in Nov 2014. An action from the agency is expected by Nov 2015. The combination therapy is also under review in the EU.
Typically, when stock falls hard there is a second wave of selling when people get home from work and check their portfolios. I bought more Friday and plan on using today to further reduce my cost basis.
Let's hope TUBE was simply giving conservative guidance.
No analyst has yet changed their rating on the stock, which is comforting.